Multiple Myeloma Insights

A recent study led by Wildes (2025) has examined a new treatment option for older adults with multiple myeloma at their first relapse. Many existing therapies can be challenging for older patients due to their side effects, including risks related to frailty, cognitive impairment, and heart issues. The study introduces a promising oral regimen combining iberdomide, ixazomib, and dexamethasone (I2D), designed specifically for patients aged 70 and above. The treatment showed an encouraging response rate, with a median progression-free survival of 13 months. Importantly, the regimen was well tolerated, even among frail patients, and had a low discontinuation rate due to side effects.

These findings are significant for older multiple myeloma patients, as they highlight a treatment that balances effectiveness with fewer side effects. The all-oral nature of the regimen makes it easier to administer compared to traditional therapies. While the study did not meet its primary target for response rates, it demonstrated meaningful improvements in patient outcomes and tolerability, making it a potential option for older adults prioritising quality of life. Patients should consult their healthcare providers to see if this approach could be suitable for them.